• GIOVEDÌ 15 APRILE 2021 - S. Anastasia martire

Beyond Batten Disease Foundation Announces Agreement with Actelion Pharmaceuticals Ltd to Provide Drug Product for BBDF-101

ATTENZIONE
Tutto il materiale presente in questo articolo è coperto da Copyright Adnkronos.com e ne è vietata la riproduzione, anche parziale.


AUSTIN, Texas, March 2, 2021 /PRNewswire/ -- Beyond Batten Disease Foundation (BBDF) is pleased to announce an agreement with Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, to provide Zavesca® (miglustat) for the development of BBDF-101, a proprietary combination of miglustat and trehalose to treat juvenile Batten disease (CLN3). Janssen will provide drug supply for the clinical trials and Extended Access Program, and right of reference to data within the Zavesca New Drug Application (NDA) to support the development of BBDF-101.



Sannioportale.it